$
290.220
+3.64(1.270%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
291.240
Open
288.010
VWAP
290.11
Vol
528.14K
Mkt Cap
20.42B
Low
286.910
Amount
153.22M
EV/EBITDA(TTM)
49.38
Total Shares
70.04M
EV
20.96B
EV/OCF(TTM)
51.56
P/S(TTM)
9.76
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
698.22M
+16.86%
1.305
+13.46%
643.90M
+18.39%
1.096
+21.75%
612.32M
+25.35%
0.923
+67.77%
Estimates Revision
The market is revising Upward the revenue expectations for Insulet Corporation (PODD) for FY2025, with the revenue forecasts being adjusted by 3.1% over the past three months. During the same period, the stock price has changed by 11.83%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.1%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.05%
In Past 3 Month
Stock Price
Go Up
up Image
+11.83%
In Past 3 Month
21 Analyst Rating
up Image
16.31% Upside
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 337.56 USD with a low forecast of 266.00 USD and a high forecast of 380.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Buy
2 Hold
0 Sell
Strong Buy
up Image
16.31% Upside
Current: 290.220
sliders
Low
266.00
Averages
337.56
High
380.00
BTIG
Buy
maintain
$330 -> $350
2025-07-14
Reason
BTIG raised the firm's price target on Insulet to $350 from $330 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
BofA
Travis Steed
Buy
maintain
$335
2025-07-08
Reason
After having caught up with Insulet management regarding the new 2026 Home Health Prospective Payment System proposal, BofA analyst Travis Steed reports that the company is confirming, "as we expected," that it does not fall under competitive bidding program given that it falls under the Part D pharmacy portion of Medicare and the proposal released last week impacts the Part B portion of Medicare. BofA maintains its Buy rating and $335 price target on Insulet, citing its market position in type 2 diabetes and patch pump and margin expansion.
Truist
Richard Newitter
Buy
initiated
$365
2025-06-17
Reason
Truist analyst Richard Newitter initiated coverage of Insulet with a Buy rating and $365 price target. Truist expects Insulet's Omnipod 5 will remain the only true tubeless and fully disposable patch pump for the forseeable future, which should allow Insulet to maintain a market leadership patch pump position within the growing Type 1 and Type 2 diabetes markets even if/when competitor patch designs begin coming to market over the next few years, the analyst tells investors in a research note. The firm sees multiple durable drivers to support a high teens+ revenue growth trajectory through 2028.
TD Cowen
Buy
upgrade
$324 -> $379
2025-06-04
Reason
TD Cowen raised the firm's price target on Insulet to $379 from $324 and keeps a Buy rating on the shares. The firm said its target increase is based on its stellar 1Q and the April appointment of Ashley McEvoy as CEO who they think will continue to press on the year-to-date drivers of T2 growth.
Goldman Sachs
Buy
initiated
$380
2025-05-29
Reason
Goldman Sachs initiated coverage of Insulet with a Buy rating and $380 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and Insulet stands to benefit from accelerating adoption of patch pump technology with the company being the only participant in the category today, the analyst tells investors in a research note. The company's pipeline also offers the potential to further strengthen its relative position, while its sustained top-line growth should support outsized adjusted EBITDA results, Goldman Sachs added.
Raymond James
Outperform
maintain
$328 -> $360
2025-05-27
Reason
Raymond James raised the firm's price target on Insulet to $360 from $328 and keeps an Outperform rating on the shares. The firm came away from spending time with Insulet's management more confident in the growth profile, and sees various sources of potential upside to Street estimates, the analyst tells investors in a research note. Insulet is one of the strongest growth stories in Med Tech, which is supported by a differentiated offering in an underpenetrated market with favorable unit economics that drive significant free cash flow potential, the firm says.

Valuation Metrics

The current forward P/E ratio for Insulet Corp (PODD.O) is 64.39, compared to its 5-year average forward P/E of 195.06. For a more detailed relative valuation and DCF analysis to assess Insulet Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
195.06
Current PE
64.39
Overvalued PE
315.03
Undervalued PE
75.09

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
68.98
Current EV/EBITDA
33.11
Overvalued EV/EBITDA
98.45
Undervalued EV/EBITDA
39.50

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
11.54
Current PS
7.66
Overvalued PS
15.50
Undervalued PS
7.57

Financials

Annual
Quarterly
FY2025Q1
YoY :
+28.82%
569.00M
Total Revenue
FY2025Q1
YoY :
+56.06%
88.80M
Operating Profit
FY2025Q1
YoY :
-31.26%
35.40M
Net Income after Tax
FY2025Q1
YoY :
-31.51%
0.50
EPS - Diluted
FY2025Q1
YoY :
-24.37%
48.10M
Free Cash Flow
FY2025Q1
YoY :
+3.48%
71.88
Gross Profit Margin - %
FY2025Q1
YoY :
+66.28%
12.77
FCF Margin - %
FY2025Q1
YoY :
-46.66%
6.22
Net Margin - %
FY2025Q1
YoY :
+32.90%
17.41
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.9M
USD
4
3-6
Months
501.9K
USD
1
6-9
Months
5.0M
USD
4
0-12
Months
4.1M
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
20.6K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
195.5K
Volume
3
6-9
Months
267.0K
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
135.7K
Volume
Months
6-9
6
483.6K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PODD News & Events

Events Timeline

2025-07-01 (ET)
2025-07-01
10:17:40
Wells says CBP proposal for CGMs expected, insulin pumps inclusion 'a surprise'
select
2025-07-01
08:52:27
Diabetes device maker shares slide after payment scheduling proposal
select
link
2025-06-24 (ET)
2025-06-24
12:14:59
Diabetes stocks rally after RFK comments on HHS campaign
select
Sign Up For More Events

News

3.0
07-21MarketWatch
15 stocks of companies set to grow sales twice as fast as the S&P 500 — analysts love them
9.0
07-14Benzinga
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes
9.5
07-08Newsfilter
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
Sign Up For More News

FAQ

arrow icon

What is Insulet Corp (PODD) stock price today?

The current price of PODD is 290.22 USD — it has increased 1.27 % in the last trading day.

arrow icon

What is Insulet Corp (PODD)'s business?

arrow icon

What is the price predicton of PODD Stock?

arrow icon

What is Insulet Corp (PODD)'s revenue for the last quarter?

arrow icon

What is Insulet Corp (PODD)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Insulet Corp (PODD)'s fundamentals?

arrow icon

How many employees does Insulet Corp (PODD). have?

arrow icon

What is Insulet Corp (PODD) market cap?